A Phase III trial comparing FULV to FULV + oxaliplatin in stage II or III carcinoma of the colon: Survival results of NSABP Protocol C-07

Carolyn Vachani, RN, MSN, AOCN
The Abramson Cancer Center of the University of Pennsylvania
Ultima Vez Modificado: 4 de junio del 2008

Translation for this article does not exist


7 Tips for Giving Smart on #givingtuesday
by Christina Bach, MSW, LCSW, OSW-C
November 25, 2015

Related News

Addition of Oxaliplatin Ups Survival in Stage II/III Colon CA

Aug 30, 2011

FULV plus oxaliplatin ups disease-free survival; overall survival improves only in patients <70 years

Bevacizumab Doesn't Prolong Survival in Stage II-III Colon CA

Dec 12, 2012

One-year of adjuvant bevacizumab + FOLFOX6 has no benefit on disease-free, overall survival

Oxaliplatin Improves Survival for Colorectal Cancer Patients

Jan 26, 2012

Improvements found in community settings, even amongst older and minority populations